Aldagen Announces Chief Financial Officer

Aldagen, Inc., a biotechnology company advancing a pipeline of clinical-stage regenerative therapies, today announced that Matthew E. Czajkowski will serve as Chief Financial Officer. Matt brings more than 25 years of financial management expertise with both private and public companies and within the banking industry.

Mr. Czajkowski previously served as Chief Financial Officer, Senior Vice President Finance and Administration, Pozen, Inc. Mr. Czajkowski took POZEN public, successfully raising $80 million during extremely challenging market conditions. Most recently, he served as Executive Vice President, Chief Financial and Administrative Officer of aaiPharma Inc. where he participated in the successful turnaround of the company. His background also includes Managing Director (New York), SG Cowen; Managing Director-Head of Corporate Finance, Wheat First Butcher Singer, Inc.; Head of Mergers and Acquisitions for Asia and Australia, Goldman Sachs & Co.; and Associate, Bankers Trust Company.

"Matt's experience in managing the financing efforts of private and public biotech companies will be a tremendous asset to us as we pursue future financing and strategic options," said Tom Amick, Chairman and Chief Executive Officer of Aldagen. "His banking experience and strong administrative and operational skills will benefit Aldagen as we continue to build an organization capable of commercializing our products."

"I am delighted to be joining Aldagen at this critical stage of their development," said Matt Czajkowski. "The company has a pipeline of extraordinary products in clinical trials and I am looking forward to working with the management team and Board of Directors to advance the company to the next stage as these products move closer to commercialization."

About Aldagen, Inc.

ALDAGEN is a biotechnology company advancing a pipeline of clinical-stage regenerative therapies. The Company has three product candidates in clinical development for chronic heart failure, critical limb ischemia and pediatric metabolic disorders and malignancies. ALDAGEN's therapeutics are produced by a proprietary technology platform that selects potent, adult stem and progenitor cells for therapeutic use. The platform yields a broad range of therapeutic cells that can be used rapidly, without culture or expansion. To learn more about ALDAGEN, please visit www.aldagen.com .

For more information, contact: Ed Field President and COO Aldagen 919-484-2571 Email Contact www.aldagen.com Michelle Linn Linnden Communications 508-419-1555 Email Contact